Coherus

Coherus is a California-based biopharmaceutical company that develops and commercializes biosimilar therapeutics for the treatment of cancer.

Business Model:

Revenue: $239.1M

Employees: 201-500

Detailed Coherus Information

Geographic Data

Coherus headquarters map

Address: 333 Twin Dolphin Drive

City: Redwood City

State: CA

Zip: 94065

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$50M

Raised Total:

$545M

Metrics

1,607,292Website Global Rank

13,144Website Monthly Traffic

Twitter Followers

Description

Coherus is a California-based biopharmaceutical company that develops and commercializes biosimilar therapeutics for the treatment of cancer.

Contact Phone:
+18007945434

Contact Email:

Coherus went public on 11/7/2014 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
11/7/2014

Ticker Symbol:
CHRS

IPO Price:
$14/share

Amount Raised:
$85M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2021 Post-IPO Equity 1 $50M Shanghai Junshi Biosciences
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences
5/2023 Post-IPO Equity $50M
9/2015 Equity $10M
12/2017 Post-IPO Equity $6.8M
3/2011 Series A $0 Medpace
Helix Ventures
Medpace
Helix Ventures
1/2007 Venture Round 1 - Sofinnova Investments
Sofinnova Investments
1/2022 Post-IPO Debt $300M Pharmakon Advisors, LP
1/2019 Post-IPO Debt 1 $75M HealthCare Royalty Partners
HealthCare Royalty Partners
HealthCare Royalty Partners
HealthCare Royalty Partners
2/2017 Post-IPO Equity $117.1M
2/2016 Post-IPO Equity $100M
1/2022 Post-IPO Debt 1 $100M Pharmakon Advisors
Pharmakon Advisors
Pharmakon Advisors
Pharmakon Advisors
11/2020 Post-IPO Equity 1 - Lord Abbett
Lord Abbett
Lord Abbett
Lord Abbett
11/2014 IPO $85M
11/2017 Equity $6.8M
5/2014 Series C 12 $54.7M Eight Roads Ventures
F-Prime Capital
Helix Ventures
KMG Capital Partners
Kohlberg Kravis Roberts
Lilly Ventures
RA Capital Management
Rock Springs Capital
Sofinnova Investments
Venrock
Viva Capital Advisors
Vivo Capital
Kohlberg Kravis Roberts
KMG Capital Partners
Viva Capital Advisors
Sofinnova Investments
Eight Roads Ventures
Rock Springs Capital
Kohlberg Kravis Roberts
5/2014 Series C $55M KKR & Co. L.P.
Venrock
RA Capital Management
Rock Springs Capital
Fidelity Biosciences
Sofinnova Ventures
Lilly Ventures
Vivo Capital
1/2012 Series B $0 Medpace
Daiichi Sankyo
Cook Pharmica, LLC
Helix Ventures
Lilly Ventures
Medpace
Daiichi Sankyo
Cook Pharmica, LLC
Helix Ventures
Lilly Ventures
7/2013 Debt Financing 1 $28M Helix Ventures
11/2020 Post-IPO Equity 1 - Lord Abbett
Lord Abbett
Lord Abbett
Lord Abbett
Announced Date Name Price
6/2023 Surface Oncology
2/2014 InteKrin

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research